Autopsy report · NCT04909515

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

“Study terminated due to business priorities”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Y-mAbs Therapeutics

Sponsor type

Industry

Conditions

Neuroblastoma

Interventions

Naxitamab; GM-CSF; Isotretinoin

Participants

0

Sites

9

Countries

Hong Kong, Russia, Singapore, South Korea

Trials that died the same way

• A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants
  “Study terminated due to business decision” (92% match in meaning)
• The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
  “Study terminated due to business and strategic decision” (92% match in meaning)
• Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
  “Study terminated for business reasons” (91% match in meaning)
• A Study of LY3549492 in Healthy Weight Adult Participants
  “Study terminated for strategic business reasons” (90% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.